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INTERVIEW
Dr. David Rimm
Feras Akbik
Yale University School of Medicine, New Haven, Connecticut
Dr. David Rimm, MD PhD, is a professor of Pathology at the Yale University School of Med-
icine specializing in developing quantitative, diagnostic techniques. His lab recently engi-
neered a fluorescence-based algorithm, Automated Quantitative Analysis (AQUA), to
analyze tissue microarrays in the hope of moving toward personalized medicine and diag-
noses.
As a physician-scientist, you’re a
practicing pathologist and an inves-
tigator interested in developing di-
agnostic techniques. What is it
about diagnostics, as opposed to
pursuing a more therapeutic ap-
proach, that drew you to pathology
and your research field?
Diagnostics is really where patholo-
gists live. We realize the importance of
proper diagnosis and the concept that even
though two people have the same disease, it
may manifest itself very differently in each
individual. Our goal as pathologists is to
look at the tissue and more carefully sub-
classify the diseases. When I first encoun-
tered pathology in medical school, I was
amazed at how subjective this process was.
Pathology seemed more of an art form than
an actual scientific discipline. That was
when I became interested in the use of mo-
lecular tools to improve the diagnosis of
disease. I wanted to develop a more objec-
tive way to treat patients appropriately as a
function of their disease sub-class.
In what ways did your experiences
as a pathologist help you think of de-
veloping something like AQUA?
As a pathologist, I’ve seen an urgent
needtomovebeyondsubjectivemethodsof
diagnosis and treatment. The best example
is Herceptin, a drug immensely valuable for
the treatment of breast cancer. Fifteen per-
cent of breast cancers are highly responsive
to Herceptin, but the drug costs $100,000
andsomewherebetween5and10percentof
thepatientswillhavesignificantcardiacside
effects. So with an outcome that important,
don’t you think we ought to have a really
goodtestthatwedon’tguessat?Youneedto
have a quantitative test that’s reproducible
and get a number and make a medical deci-
sion based on a reproducible number.
Back in the late 1990s, molecular di-
agnostics was just coming of age; there
were only a handful of tests you could do.
We relied heavily on immunohistochem-
istry, but because it was so fraught with
variables and poorly controlled, it was not
respected as a molecular test. “Molecular”
had come to mean a DNA-based test, and
we were making great progress in decipher-
ing the genetic markers for various sub-
classes of disease. The use of fluorescence
instead of antibody stains was the first step
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The true turning point was the invention
of the tissue microarray in 1998. This tech-
nique was revolutionary because it reduced
a specimen to a 0.6mm diameter piece of tis-
sue on a slide. We regarded that one slide as
representative of the whole tumor, even
though it comprised 0.03 percent of the
whole tumor. With such a small sample, we
thought it possible to be rigorously quantita-
tive and count every single molecule in that
little spot.The goal was to do away with the
traditional, arbitrary scoring system of +2,
+3, etc. and calculate a specific concentra-
tion, such as 2 µg, for a given molecular
marker. That was the vision, but we could
not find a piece of software to do it. That
was when Dr. Richard Camp, a senior asso-
ciate research scientist, wrote the first ver-
sion ofAQUAin visual basic.
What makes AQUA so different from
the software that came before it?
Today, most software utilizes what is
known as feature extraction. That’s when
you have a contrast generating edge, and the
best example of this is the nucleus of a cell.
You look through the cell and anytime you
find something round, it’s a nucleus.AQUA,
on the other hand, makes use of fluorescence
to define a location within the cell. We want
everything to be defined by a molecular def-
inition rather than by contrasting shapes. In
the case of the nucleus, we take advantage
of the fluorescent dye, DAPI, which binds
to DNA. By quantifying DAPI-positive pix-
els, AQUA gives the nucleus a molecular
definition without using feature extraction.
So how do we arrive at a concentration?
Well, a measurement is simply a numerator
over a denominator.We have our denomina-
tor, the compartment, and now we need our
numerator, which is just the sum of all the
intensities of our target molecule. For exam-
ple, we can take the sum of all the intensities
of estrogen receptors signals and divide that
by the sum of the areas, and we have a vir-
tual concentration.
In what settings have you been able
to test AQUA against pathologists
or have validated the system in a
clinical model?
Since the first publication in 2002,
AQUAhas been used in many different set-
tings. Many times, it allows us to see things
that the pathologist can’t see. One reason is
that pathologists, and human beings in gen-
eral, are able to tell dark from light, but they
are generally bad at reproducibly judging
shadesofgray.AQUAtendstodobetterthan
the pathologist at measuring subtle differ-
ences. One of the first studies looked at Her-
2.Apathologist can see the high level peak,
probably only missing 10 to 15 percent of
those. But what happens with low-level ex-
pression? AQUA is especially useful when
you have to tell the difference between low
and very low or high and very high.Another
advantage ofAQUAstems from the fact that
human beings can’t calculate ratios in their
heads. AQUA can measure the signals from
the nucleus and the cytoplasm and then ratio
the two. By internally normalizing the
scores, we can get rid of individual variation
inproteinexpressionlevels.Finally,themost
important feature of AQUA is that we can
multiplex. It’s clear that if you want to clas-
sify and do diagnostic things, one protein is
not going to be enough. For example, we
now have an algorithm of six different pro-
teins to predict a patient’s response to Her-
ceptin.
So what you’re saying is that using
AQUA in a multiplex setting is going
to lead to a more specific or person-
alized diagnosis?
Absolutely.IthinkAQUAwillleadusto
a more personalized diagnosis of tumor sub-
class.Forexample,wecanusetheexpression
profile of multiple markers to identify those
patients with the type of tumor that is more
likely to recur. We can then give those pa-
tientsextratreatmentaftertheirresectionasa
protectivemeasure.ThefirstDNA-basedtest,
Oncotype DX, is being used now. It analyzes
the sequence of 21 genes to fractionate pa-
tients with the same disease into sub-classes.
Wecantellwhichpatientsneedmoretherapy.
AQUA will be different in that it analyzes
proteinexpressionratherthanaDNAorRNA
sequence. Instead of looking at 21 genes likeAkbik: Interview with Dr. David Rimm 185
Oncotype DX, we now can analyze the ex-
pression of only five proteins. Looking at the
protein level is more accurate approach.
So why do you use a proteomic ap-
proach instead of a genomic one?
Well, for two reasons. Genomics is the
grammar, but proteins are the literature. We
need all the letters to make the words, but the
functionalthingsaretheresponsibilitiesofthe
proteins. Even if you had RNAexpression, it
doesn’tmeanthere’sproteinexpression,or,if
it was, it might not still be around while the
RNAisstillthere.Also,assessingtheactivity
of a protein by looking at post-translational
modifications is a lot more information-rich
than simply knowing if the protein is there or
not.UsingAQUA,wecanmeasurephospho-
rylationstatesandseeitchangeaswegivepa-
tients a particular drug. We certainly can’t do
that by eye. We really need to have a number
and see if that number goes down.
What do you think it’s going to take to
make AQUA, and technology like it, a
more standard fixture in clinical prac-
tice and research? How do you think
it fits into the future of medicine?
That’s the real challenge, because if you
candosomethinginyourlabthat’sreallycool
but nobody else in the world is doing it, it’s
not that valuable. The next step is forAQUA
to get out there and be employed in clinical
trials. We’re involved now in a trial aimed at
predictingtheresponsetoHerceptin.Ifwecan
demonstratethatusingAQUAisbetteratpre-
dicting a response to Herceptin than by look-
ing at Her-2 expression alone, that might
makeotherpeoplewanttotryitorbuyit.On-
cologists may want to do the AQUA test in-
steadofthetraditionalimmunohistochemistry
test to decide whether to prescribe Herceptin.
What’s the limitation for this technol-
ogy, or what kinds of things could
AQUA not do?
AQUA requires a tissue sample, which
means performing a biopsy. This is a bit
more invasive than imaging-based diag-
noses, like MRI, PET, etc. Another disad-
vantage is that you can’t just look under the
microscope and get the answer right away.
AQUA takes time and standardization. It
may be more expensive, but it costs nothing
compared to the drug at $100,000 per year.
CanyoutelluswhereAQUAgoesfrom
here?
In2004,HistoRxwasfounded,andthey
are the exclusive licensee of the software.
Sometimelaterthisyear,theywillreleasethe
first test so pathologists can use it in the clin-
ical setting to predict responses to therapies
inmoresubtlewaysthanwecancurrentlydo
by eye. Not too long after that, there may be
tests that can predict whether patients do or
don’t need chemotherapy or if a tumor will
recur or not. The commercialization of
AQUAwillallowittoreachagreaternumber
of patients.
How long will it take to get this tech-
nology to everyday use? What needs
to happen?
I initially guessed it was going to be a
few years, but it’s clearly going to take a lot
longer than that. It turns out that a diagnostic
test has to go through the same trials as
drugs have to go through to be accepted. A
drug can take 10 to 12 years, and we might
see the same thing with diagnostics. We’re
pretty far along the pathway, so we might
see the first inkling of it this year, but my
hope is we’ll seeAQUAas a prominent fix-
ture in pathology in three to five more years.